Related Experiment Video

Updated: Sep 5, 2025

Zebra II as A Novel System to Record Electrophysiological Signals in Zebrafish
06:15

Zebra II as A Novel System to Record Electrophysiological Signals in Zebrafish

Published on: August 16, 2024

513

Effects of Amiodarone and Esmolol for Heart Rate and Cardiovascular Changes

Hao Wang1, Fengping Lei2, Lei Bai3

  • 1Department of Cardiology, The First People's Hospital of Li County, Longnan 742500, Gansu, China.

Emergency Medicine International
|July 7, 2022
PubMed

Insights

Amiodarone and esmolol combination therapy effectively treats heart rate disorders and myocardial infarction, improving cardiac function and patient quality of life with minimal adverse effects.

Area of Science:

  • Cardiology
  • Pharmacology

Background:

  • Heart rate disorders and myocardial infarction pose significant health challenges.
  • Amiodarone and esmolol are established treatments for cardiac conditions.

Purpose of the Study:

  • To evaluate the efficacy and safety of combined amiodarone and esmolol treatment for heart rate disorders and myocardial infarction.
  • To compare the outcomes of combined therapy versus amiodarone alone.

Main Methods:

  • A retrospective analysis of 76 patients with cardiopathy from July 2019 to October 2021.
  • Comparison of blood pressure, treatment effectiveness, adverse reactions, myocardial markers, ECG, and heart function indicators between a combined treatment group and a control group (amiodarone only).

Main Results:

  • The combined group showed significantly higher systolic pressure and effective treatment rates compared to the control group.
  • Both groups experienced significant reductions in heart rate and QT intervals, with greater reduction in the combined group.
  • Myocardial marker levels were significantly reduced, and quality of life significantly increased in the combined group compared to the control group.
  • Adverse reaction rates were comparable between the two groups.

Conclusions:

  • Combined amiodarone and esmolol treatment demonstrates superior outcomes in improving cardiac function, reducing myocardial markers, and enhancing patient quality of life.
  • The combination therapy offers a promising and safe treatment strategy for heart rate disorders and myocardial infarction.
Abstract

More Related Videos

Methods for ECG Evaluation of Indicators of Cardiac Risk, and Susceptibility to Aconitine-induced Arrhythmias in Rats Following Status Epilepticus08:28

Methods for ECG Evaluation of Indicators of Cardiac Risk, and Susceptibility to Aconitine-induced Arrhythmias in Rats Following Status Epilepticus

Published on: April 5, 2011

17.9K
Electrocardiogram Recordings in Anesthetized Mice using Lead II04:16

Electrocardiogram Recordings in Anesthetized Mice using Lead II

Published on: June 20, 2020

13.1K

Related Concept Videos

Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers01:24

Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers

Adrenergic stimulation generally impacts cardiac rate and rhythm. Specifically, stimulation of the β-adrenoceptors triggers an increase in intracellular calcium ion influx and pacemaker currents, which may cause arrhythmias. Catecholamines like adrenaline also demonstrate β2-adrenoceptor-mediated hypokalemia, impacting cardiac action potential and disrupting the normal cardiac rhythm. Class II antiarrhythmic drugs are β-adrenoceptor antagonists or β-blockers, which...
839
Factors Influencing Heart Rate01:30

Factors Influencing Heart Rate

The heart rate, or pulse rate, is a vital indicator of cardiovascular health. It reflects the number of times the heart beats per minute. Various physiological and environmental factors influence heart rate, increasing or decreasing cardiac output. Understanding these factors is crucial for assessing heart function and identifying potential health issues.
Let us explore the significant factors affecting heart rate, including age, body temperature, posture, acute pain, chemical influences,...
3.5K
Heart Failure Drugs: β-Blockers01:22

Heart Failure Drugs: β-Blockers

β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
430
Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers01:12

Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers

Class III antiarrhythmic drugs are a group of medications that can prolong action potentials in the heart. They achieve this by blocking potassium channels or enhancing inward currents from sodium channels. However, these drugs have a unique property of "reverse use-dependence," which is most pronounced at slower heart rates and can lead to torsades de pointes—a specific type of arrhythmia. However, it is essential to note that excessive QT interval prolongation—a measure of...
1.2K
Cardiac Output I:Effect of Heart Rate on Cardiac Output01:19

Cardiac Output I:Effect of Heart Rate on Cardiac Output

Cardiac Output
Cardiac output (CO) refers to the total amount of blood ejected by one of the ventricles in liters per minute (L/min). In a resting adult, CO ranges from 5 to 6 L/min, adjusting according to the body's metabolic requirements.
Effect of Heart Rate on Cardiac Output
Cardiac output adapts to metabolic demands during stress, physical activity, or illness. The autonomic nervous system regulates heart rate via the sinoatrial node. The parasympathetic nervous system decreases heart...
1.2K
Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers01:20

Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers

Class IV antiarrhythmic drugs, such as verapamil and diltiazem, block calcium channels. They primarily affect the heart, slowing the conduction in calcium-dependent tissues like the SA and AV nodes. These drugs manage reentrant supraventricular tachycardia (SVT) and reduce ventricular rate in atrial flutter/fibrillation.
Verapamil, a calcium channel blocker, inhibits calcium movement across myocardial cell membranes and vascular smooth muscle. This results in the dilation of coronary and...
979